Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.31 |
| ▸ | MET | P08581 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6102611 | 0.91 | LMNA (0.33) | LMNAL3MBTL1MET | |
| SCHEMBL6102849 | 0.89 | KDM4E (0.36) | LMNAL3MBTL1KCNH2MET | |
| SCHEMBL6102802 | 0.88 | LMNA (0.31) | LMNAL3MBTL1KCNH2 | |
| SCHEMBL6102685 | 0.87 | ADORA2A (0.34) | LMNAL3MBTL1KCNH2 | |
| SCHEMBL6101337 | 0.86 | KCNH2 (0.32) | KCNH2MET | |
| SCHEMBL6101761 | 0.86 | KCNH2 (0.31) | LMNAL3MBTL1KCNH2 | |
| SCHEMBL6101435 | 0.85 | LMNA (0.35) | LMNAL3MBTL1METPDE10A | |
| SCHEMBL6102336 | 0.85 | AXL (0.32) | KCNH2 | |
| SCHEMBL6498026 | 0.85 | KCNH2 (0.31) | KCNH2 | |
| SCHEMBL6102506 | 0.84 | PDE10A (0.34) | LMNAL3MBTL1PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130150351-A1 | METHODS AND COMPOSITIONS FOR TREATING A SUBJECT FOR CENTRAL NERVOUS SYSTEM (CNS) INJURY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-06-13 | — | — | US | disclosed |
| US-20060014746-A1 | Heteroaryl substituted fused bicyclic heteroaryl compounds as GABAA receptor ligands | NEUROGEN CORPORATION | 2006-01-19 | — | — | US | disclosed |
| US-6936617-B2 | Heteroaryl substituted fused bicyclic heteroaryl compound as GABAA receptor ligands | NEUROGEN CORPORATION (US) | 2005-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014746-A1 | Heteroaryl substituted fused bicyclic heteroaryl compounds as GABAA receptor ligands | GABRA5, GABRA2, GABBR1 | LMNA 3964/4885L3MBTL1 4557/4885KCNH2 566/4885 |
| US-20130150351-A1 | METHODS AND COMPOSITIONS FOR TREATING A SUBJECT FOR CENTRAL NERVOUS SYSTEM (CNS) INJURY | GABBR2, GABBR1, GABRR3 | LMNA 1488/4885L3MBTL1 4184/4885KCNH2 1618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.